| Identification | Back Directory | [Name]
Carbamic acid, N-[6-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]-1H-benzimidazol-2-yl]-, ethyl ester | [CAS]
2170491-77-5 | [Synonyms]
AMXI-5001
Carbamic acid, N-[6-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]-1H-benzimidazol-2-yl]-, ethyl ester | [Molecular Formula]
C25H20FN5O3 | [MOL File]
2170491-77-5.mol | [Molecular Weight]
457.46 |
| Chemical Properties | Back Directory | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
10.19±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Biological Activity]
AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors[1]. | [storage]
Store at -20°C | [References]
[1]. Lemjabbar-Alaoui H, et al. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020;10(8):2649-2676. |
|
|